Nymox Pharmaceutical Corp (NASDAQ:NYMX)

CAPS Rating: 1 out of 5

A biopharmaceutical company with three proprietary products on the market and a R&D of drug & diagnostic products in development for the treatment of enlarged prostate, Alzheimer's disease contamination of food and drink products and bacterial infections.


Player Avatar mshakin1 (< 20) Submitted: 5/27/2010 2:50:11 PM : Outperform Start Price: $4.71 NYMX Score: -174.63

The NYMOX drug for BPH, NX1207, is head and shoulders above all the existing drugs for this ailment, which affects tens of millions of middle age and elderly men. Not only is NX1207 so much more effective than Flomax and Avodart is decreasing BPH, but it also doesn't have the sexual side effects. And instead of taking hose drugs every day forever, NX1207 is an injection administered in a urologist's office only once every several years.This drug has tremendous potential. To become a blockbuster, it doesn't have to be recognized as a great drug by consumers, but rather by urologists, who will be well aware of how much better it is than the alternative oral drugs.

Member Avatar sr1111 (< 20) Submitted: 10/21/2011 5:56:33 PM
Recs: 0

I think that NYMX has finally found a winner with the NX 1207.

Featured Broker Partners